Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 165
Filter
1.
J Med Food ; 24(2): 111-115, 2021 Feb.
Article in English | MEDLINE | ID: mdl-32397850

ABSTRACT

To evaluate the effect of berberine (BBR) plus bezafibrate administration on the lipid profile of patients with mixed dyslipidemia. A double-blind randomized pilot clinical trial with parallel groups was carried out in 36 patients, aged 30-60 years with mixed dyslipidemia [triglycerides (TG) ≥1.7 mM and total cholesterol (TC) ≥5.2 mM]. Patients were assigned to 3 groups of 12 patients each, receiving oral administration during 90 days of BBR 500 mg t.i.d., bezafibrate 400 mg b.i.d., or BBR 500 mg t.i.d. plus bezafibrate 400 mg b.i.d, respectively. Clinical evaluation, lipid profile, glucose, creatinine, and uric acid levels were measured before and after the pharmacological intervention. Kruskal-Wallis, Wilcoxon, Mann-Whitney U, and χ2 tests were used for statistical analyses; a P ≤ .05 was considered statistically significant. BBR reduced TC levels. Bezafibrate decreased TG, TC, low-density lipoprotein cholesterol (LDL-C), and very low-density lipoprotein (VLDL) concentrations. BBR plus bezafibrate decreased TG (2.6 ± 0.8 vs. 1.3 ± 0.7 mM, P = .007), TC (6.3 ± 0.7 vs. 4.6 ± 1.2 mM, P = .005), LDL-C (3.4 ± 0.6 vs. 2.2 ± 1.3 mM, P = .037), and VLDL (0.5 ± 0.2 vs. 0.2 ± 0.1 mM, P = .007) levels. Bezafibrate and BBR plus bezafibrate significantly decreased TG, TC, LDL-C, and VLDL concentrations, and thus, remitting the diagnosis of mixed dyslipidemia in 90% of the patients.


Subject(s)
Berberine/administration & dosage , Bezafibrate , Dyslipidemias , Adult , Bezafibrate/administration & dosage , Dyslipidemias/drug therapy , Humans , Lipids/blood , Middle Aged , Pilot Projects , Triglycerides/blood
2.
Biosci Rep ; 41(1)2021 01 29.
Article in English | MEDLINE | ID: mdl-33289496

ABSTRACT

Drug repurposing is a cost-effective means of targeting new therapies for cancer. We have examined the effects of the repurposed drugs, bezafibrate, medroxyprogesterone acetate and valproic acid on human osteosarcoma cells, i.e., SAOS2 and MG63 compared with their normal cell counterparts, i.e. mesenchymal stem/stromal cells (MSCs). Cell growth, viability and migration were measured by biochemical assay and live cell imaging, whilst levels of lipid-synthesising enzymes were measured by immunoblotting cell extracts. These drug treatments inhibited the growth and survival of SAOS2 and MG63 cells most effectively when used in combination (termed V-BAP). In contrast, V-BAP treated MSCs remained viable with only moderately reduced cell proliferation. V-BAP treatment also inhibited migratory cell phenotypes. MG63 and SAOS2 cells expressed much greater levels of fatty acid synthase and stearoyl CoA desaturase 1 than MSCs, but these elevated enzyme levels significantly decreased in the V-BAP treated osteosarcoma cells prior to cell death. Hence, we have identified a repurposed drug combination that selectively inhibits the growth and survival of human osteosarcoma cells in association with altered lipid metabolism without adversely affecting their non-transformed cell counterparts.


Subject(s)
Bezafibrate/administration & dosage , Bone Neoplasms/pathology , Cell Proliferation/drug effects , Medroxyprogesterone Acetate/administration & dosage , Mesenchymal Stem Cells/drug effects , Osteosarcoma/pathology , Valproic Acid/administration & dosage , Bone Neoplasms/drug therapy , Bone Neoplasms/enzymology , Cell Line, Tumor , Down-Regulation , Drug Repositioning , Drug Therapy, Combination , Fatty Acid Synthases/metabolism , Humans , Mesenchymal Stem Cells/cytology , Osteosarcoma/drug therapy , Osteosarcoma/enzymology , Stearoyl-CoA Desaturase/metabolism , Up-Regulation
3.
Gastroenterology ; 160(3): 734-743.e6, 2021 02.
Article in English | MEDLINE | ID: mdl-33031833

ABSTRACT

BACKGROUND AND AIMS: Pruritus may seriously impair quality of life in patients with cholestatic diseases such as primary or secondary sclerosing cholangitis (PSC, SSC) and primary biliary cholangitis (PBC). Pharmacologic strategies show limited efficacy and can provoke serious side effects. We hypothesized that bezafibrate, a broad peroxisome proliferator-activated receptor (PPAR) agonist, relieves cholestasis-associated itch by alleviating hepatobiliary injury. The aim of this investigator-initiated FITCH trial (Fibrates for cholestatic ITCH) was to assess effects of bezafibrate on pruritus in patients with PSC, PBC, and SSC. METHODS: Patients with moderate to severe pruritus (≥5 of 10 on visual analog scale [VAS]) due to PSC, PBC, or SSC were recruited for this double-blind, randomized, placebo-controlled trial between 2016 and 2019. Patients received once-daily bezafibrate (400 mg) or placebo for 21 days. The primary end point was ≥50% reduction of pruritus (VAS; intention-to-treat). RESULTS: Of 74 randomized patients, 70 completed the trial (95%; 44 PSC, 24 PBC, 2 SSC). For the primary end point, bezafibrate led in 45% (41% PSC, 55% PBC) and placebo in 11% to ≥50% reduction of severe or moderate pruritus (P = .003). For secondary end points, bezafibrate reduced morning (P = .01 vs placebo) and evening (P = .007) intensity of pruritus (VAS) and improved the validated 5D-Itch questionnaire (P = .002 vs placebo). Bezafibrate also reduced serum alkaline phosphatase (-35%, P = .03 vs placebo) correlating with improved pruritus (VAS, P = .01) suggesting reduced biliary damage. Serum bile acids and autotaxin activity remained unchanged. Serum creatinine levels tended to mildly increase (3% bezafibrate, 5% placebo, P = .14). CONCLUSIONS: Bezafibrate is superior to placebo in improving moderate to severe pruritus in patients with PSC and PBC. TRIAL REGISTRATION: Netherlands Trial Register, ID: NTR5436 (August 3, 2015), ClinicalTrials.gov ID: NCT02701166 (March 2, 2016).


Subject(s)
Bezafibrate/administration & dosage , Cholangitis, Sclerosing/complications , Liver Cirrhosis, Biliary/complications , Pruritus/drug therapy , Adult , Bezafibrate/adverse effects , Cholangitis, Sclerosing/drug therapy , Double-Blind Method , Female , Humans , Liver Cirrhosis, Biliary/drug therapy , Male , Middle Aged , Placebos/administration & dosage , Placebos/adverse effects , Pruritus/diagnosis , Pruritus/etiology , Pruritus/psychology , Quality of Life , Severity of Illness Index , Treatment Outcome , Visual Analog Scale
5.
Int J Nanomedicine ; 15: 705-715, 2020.
Article in English | MEDLINE | ID: mdl-32099359

ABSTRACT

BACKGROUND: Bezafibrate is a BCS class II drug as it presents very low solubility in water; therefore, its bioavailability after oral administration is very poor. The aim of this work was to enhance solubility and dissolution rate of bezafibrate in water in order to enhance its oral bioavailability. METHODS: Several formulations were prepared using PVP K30 and Cremophor ELP employing the solvent-evaporation method and the electrospraying technique. Solubility, release rate, bioavailability in male Sprague Dawley rats, and lipid profile attributes in Wistar rats were assessed in comparison with bezafibrate plain powder. Solid-state characterization was carried out using X-ray diffraction (XRD) analysis, differential scanning calorimetry (DSC), Fourier transform infrared (FTIR) spectroscopy and scanning electron microscopy (SEM). RESULTS: All the formulations exerted positive effect towards the desired goal. In particular, the optimized formulation furnished about 14-fold enhanced solubility and 85.48 ± 10.16% drug was released in 10 min as compared with bezafibrate alone (4.06 ± 2.59%). The drug existed in the amorphous state in the prepared sample as confirmed by XRD and DSC, whilst no drug-excipient interactions were observed through FTIR analysis. Moreover, SEM revealed smooth-surfaced spherical particles of the optimized formulation. A 5.5-fold higher oral bioavailability was achieved with the optimized formulation in comparison with bezafibrate plain powder. Also, TG, LDL and TC were decreased, and HDL was increased considerably in HFD-treated rats. CONCLUSION: The optimized formulation consisting of bezafibrate, PVP K30 and cremophor ELP (1/12/1.5, w/w/w) might be a capable drug delivery system for orally administering poorly water-soluble bezafibrate with improved bioavailability and antihyperlipidemic effects.


Subject(s)
Bezafibrate/pharmacology , Drug Delivery Systems/methods , Hypolipidemic Agents/pharmacology , Nanospheres/chemistry , Polymers/chemistry , Administration, Oral , Animals , Bezafibrate/administration & dosage , Bezafibrate/blood , Bezafibrate/pharmacokinetics , Biological Availability , Calorimetry, Differential Scanning , Hydrophobic and Hydrophilic Interactions , Hypolipidemic Agents/administration & dosage , Hypolipidemic Agents/blood , Hypolipidemic Agents/pharmacokinetics , Lipids/chemistry , Male , Nanospheres/ultrastructure , Polyethylene Glycols/chemistry , Povidone/chemistry , Powders , Rats, Sprague-Dawley , Solubility , Spectroscopy, Fourier Transform Infrared , X-Ray Diffraction
6.
J Gastroenterol Hepatol ; 35(4): 663-672, 2020 Apr.
Article in English | MEDLINE | ID: mdl-31677185

ABSTRACT

BACKGROUND AND AIM: Primary biliary cholangitis (PBC) patients who are refractory to ursodeoxycholic acid (UDCA) are at risk for progression to cirrhosis and liver failure. Bezafibrate could be an alternative second-line therapeutic option in these patients. This study aimed to evaluate the long-term outcome(s) of combined UDCA and bezafibrate therapy in UDCA-refractory PBC patients and identify prognostic factors. METHODS: Among 445 patients treated with UDCA, 150 patients inadequately responded to UDCA monotherapy and received long-term UDCA plus bezafibrate (median, 15 years). Data from these patients were used for this retrospective analysis. RESULTS: Combination therapy resulted in significant improvements in serum biochemistry and liver transplantation risk estimated using the UK-PBC-risk and the GLOBE scores. The cumulative normalization rates of alkaline phosphatase, gamma-glutamyltransferase, and immunoglobulin M (IgM) were significantly higher in patients without cirrhosis-related symptoms or liver-related events than in those with them. Overall, IgM constantly emerged as a significant factor associated with cirrhosis-related symptoms and liver-related events at all time points. Cumulative survival rates were significantly lower in patients with IgM ≥ 240 mg/dL than in patients with IgM < 240 mg/dL. Thus, normalization of IgM levels was a good surrogate predictor of long-term prognosis. None of the patients discontinued combination therapy due to any adverse events during the follow-up period. CONCLUSIONS: Our findings point to the beneficial effects of long-term UDCA plus bezafibrate combination therapy for UDCA-refractory PBC patients, and IgM response can be a useful predictive biomarker of long-term clinical outcomes.


Subject(s)
Bezafibrate/administration & dosage , Immunoglobulin M/blood , Liver Cirrhosis, Biliary/diagnosis , Liver Cirrhosis, Biliary/drug therapy , Ursodeoxycholic Acid/administration & dosage , Biomarkers/blood , Drug Therapy, Combination , Female , Humans , Liver Cirrhosis, Biliary/mortality , Male , Middle Aged , Prognosis , Retrospective Studies , Survival Rate , Time Factors , Treatment Outcome
7.
Psychiatry Res ; 281: 112584, 2019 11.
Article in English | MEDLINE | ID: mdl-31586837

ABSTRACT

The present study aimed to investigate the effect of bezafibrate on glucolipid abnormalities induced by antipsychotics in schizophrenia. Patients in the treatment group (group A) were treated with antipsychotics and a daily dose of 200 mg bezafibrate for 12 weeks, and patients in the control group (group B) were treated with antipsychotics; sugar, fat and weight changes before and after the treatment were compared between the two groups. Before treatment the differences in TG, TC, LDL-C, HDL-C, body weight and blood glucose between groups A and B were not statistically significant. However, in group B, levels of TG, TC, LDL-C, body weight and blood glucose after treatment showed statistically significant increases, although levels of HDL-C did not register any statistically significant change. By contract, in group A, there were no statistically significant changes in any of the variables measured. Bezafibrate can prevent an increase in sugar, fat and weight gain in treating schizophrenia patients with antipsychotics, and low doses of bezafibrate are safe in the antipsychotic treatment for schizophrenia.


Subject(s)
Antipsychotic Agents/administration & dosage , Bezafibrate/administration & dosage , Blood Glucose/drug effects , Hypolipidemic Agents/administration & dosage , Risperidone/administration & dosage , Schizophrenia/drug therapy , Adolescent , Adult , Antipsychotic Agents/adverse effects , Blood Glucose/metabolism , Body Weight/drug effects , Body Weight/physiology , Drug Therapy, Combination , Female , Humans , Male , Middle Aged , Risperidone/adverse effects , Schizophrenia/blood , Weight Gain/drug effects , Weight Gain/physiology , Young Adult
8.
Neurotox Res ; 35(4): 809-822, 2019 May.
Article in English | MEDLINE | ID: mdl-30850947

ABSTRACT

3-Methylglutaric acid (MGA) is an organic acid that accumulates in 3-methylglutaconic (MGTA) and 3-hydroxy-3-methylglutaric (HMGA) acidurias. Patients affected by these disorders present with neurological dysfunction that usually appears in the first years of life. In order to elucidate the pathomechanisms underlying the brain injury in these disorders, we evaluated the effects of MGA administration on redox homeostasis, mitochondrial respiratory chain activity, and biogenesis in the cerebral cortex of developing rats. Neural damage markers and signaling pathways involved in cell survival, and death were also measured after MGA administration. Furthermore, since the treatment for MGTA and HMGA is still limited, we tested whether a pre-treatment with the pan-peroxisome proliferator-activated receptor (PPAR) agonist bezafibrate could prevent the alterations caused by MGA. MGA provoked lipid peroxidation, increased heme oxygenase-1 content, and altered the activities of antioxidant enzymes, strongly suggestive of oxidative stress. MGA also impaired mitochondrial function and biogenesis by decreasing the activities of succinate dehydrogenase and various respiratory chain complexes, as well as the nuclear levels of PGC-1α and NT-PGC-1α, and cell content of Sirt1. AMPKα1 was further increased by MGA. Neural cell damage was also observed following the MGA administration, as verified by decreased Akt and synaptophysin content and reduced ERK phosphorylation, and by the increase of active caspase-3 and p38 and Tau phosphorylation. Importantly, bezafibrate prevented MGA-elicited toxic effects towards mitochondrial function, redox homeostasis, and neural cell injury, implying that this compound may be potentially used as an adjunct therapy for MGTA and HMGA and other disorders with mitochondrial dysfunction.


Subject(s)
Bezafibrate/administration & dosage , Brain Injuries/metabolism , Meglutol/analogs & derivatives , Organelle Biogenesis , Animals , Brain Injuries/chemically induced , Brain Injuries/prevention & control , Caspase 3/metabolism , MAP Kinase Signaling System/drug effects , Male , Meglutol/administration & dosage , Oxidation-Reduction , Oxidative Stress/drug effects , Rats, Wistar , Synaptophysin/metabolism , tau Proteins/metabolism
9.
Hepatology ; 70(6): 2035-2046, 2019 12.
Article in English | MEDLINE | ID: mdl-30737815

ABSTRACT

In Japan, bezafibrate (BF) is a second-line agent for primary biliary cholangitis (PBC) that is refractory to ursodeoxycholic acid (UDCA) treatment. From a retrospective cohort (n = 873) from the Japan PBC Study Group, we enrolled 118 patients who had received UDCA monotherapy for at least 1 year followed by combination therapy with UDCA+BF for at least 1 year. GLOBE and UK-PBC scores after UDCA monotherapy (i.e., immediately before UDCA+BF combination therapy) were compared with those after 1 year of UDCA+BF combination therapy. The real outcomes of enrolled patients estimated by Kaplan-Meier analysis were compared with the predicted outcomes calculated using GLOBE and UK-PBC scores. In addition, the hazard ratio of BF treatment was calculated using propensity score analysis. The mean GLOBE score before the combination therapy was 0.504 ± 0.080, which improved significantly to 0.115 ± 0.085 (P < 0.0001) after 1 year of combination therapy. The real liver transplant-free survival of enrolled patients was significantly better than that predicted by GLOBE score before introducing BF. Combination therapy did not significantly improve the real rates of liver transplantation or liver-related death compared with those predicted by UK-PBC risk score before introducing BF, but the predicted risk was significantly reduced by the addition of BF (P < 0.0001). Cox regression analysis with inverse probability of treatment weighting showed that the addition of BF significantly reduced the hazard of liver transplant or liver-related death in patients who, after 1 year of UDCA monotherapy, had normal serum bilirubin (adjusted hazard ratio 0.09, 95% confidence interval 0.01-0.60, P = 0.013). Conclusion: Addition of BF to UDCA monotherapy improves not only GLOBE and UK-PBC scores but also the long-term prognosis of PBC patients, especially those with early-stage PBC.


Subject(s)
Bezafibrate/therapeutic use , Cholangitis/drug therapy , Adult , Aged , Aged, 80 and over , Bezafibrate/administration & dosage , Cholangitis/mortality , Female , Humans , Male , Middle Aged , Propensity Score , Proportional Hazards Models , Retrospective Studies , Treatment Outcome , Ursodeoxycholic Acid/administration & dosage , Ursodeoxycholic Acid/therapeutic use
10.
BMJ Case Rep ; 11(1)2018 Nov 28.
Article in English | MEDLINE | ID: mdl-30567142

ABSTRACT

Acute pancreatitis (AP) is a potentially life-threatening complication of severe hypertriglyceridaemia, which is the third most common cause of AP after gallstone disease and alcohol excess. Standard therapy involves the use of lipid-lowering agents, low-molecular-weight heparin and insulin infusion. In some cases, when standard medical therapies fail, non-pharmacological methods based on the removal of triglycerides with therapeutic plasma exchange can provide positive results in the acute phase. There are currently no guidelines covering management in the acute phase, however, these approaches should be considered in severe or very severe hypertriglyceridaemia. Here, we report the case of a 37-year-old man with recurrent AP due to hypertriglyceridaemia and review the literature.


Subject(s)
Hypertriglyceridemia/complications , Pancreatitis/diagnosis , Pancreatitis/etiology , Acute Disease , Administration, Intravenous , Adult , Bezafibrate/administration & dosage , Bezafibrate/therapeutic use , Humans , Hypertriglyceridemia/drug therapy , Hypoglycemic Agents/therapeutic use , Hypolipidemic Agents/therapeutic use , Insulin/administration & dosage , Insulin/therapeutic use , Male , Pancreatitis/drug therapy , Plasma Exchange/methods , Treatment Outcome , Triglycerides/blood
11.
Cancer Immunol Res ; 6(11): 1375-1387, 2018 11.
Article in English | MEDLINE | ID: mdl-30143538

ABSTRACT

Although PD-1 blockade cancer immunotherapy has shown potential for a wide range of patients with cancer, its efficacy is limited, in part, due to the loss of effector cytotoxic T lymphocytes (CTLs) via terminal differentiation-induced apoptosis. We previously demonstrated that mitochondrial activation, by the agonists of peroxisome proliferator-activated receptor γ (PPARγ) coactivator 1-α (PGC-1α)/transcription factor complexes, had synergistic effects with a PD-1-blocking monoclonal antibody in a mouse tumor model. In the current study, we examined the molecular mechanism of the synergistic effects of bezafibrate, an agonist of PGC-1α/ PPAR complexes, which enhanced the tumoricidal effects of PD-1 blockade. Bezafibrate activated CTL mitochondria and upregulated oxidative phosphorylation as well as glycolysis, resulting in more proliferation of naïve T cells and improved effector function in CTLs. Bezafibrate also increased fatty acid oxidation (FAO) and mitochondrial respiratory capacity, which supports the extra energy demands of cells in emergencies, allowing cell survival. Carnitine palmitoyl transferase 1 (Cpt1), which is needed for FAO, and Bcl2 were both upregulated. Cpt1 and Bcl2 can form a complex to prevent apoptosis of CTLs. Together, these results indicate that bezafibrate increases or maintains the number of functional CTLs by activating mitochondrial and cellular metabolism, leading in turn to enhanced antitumor immunity during PD-1 blockade. Cancer Immunol Res; 6(11); 1375-87. ©2018 AACR.


Subject(s)
Bezafibrate/pharmacology , CD8-Positive T-Lymphocytes/drug effects , Fatty Acids/metabolism , Peroxisome Proliferator-Activated Receptors/metabolism , Programmed Cell Death 1 Receptor/antagonists & inhibitors , Animals , Antibodies, Monoclonal/administration & dosage , Antibodies, Monoclonal/pharmacology , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Bezafibrate/administration & dosage , CD8 Antigens/genetics , Cell Differentiation , Mice, Inbred BALB C , Mice, Inbred C57BL , Mitochondria/drug effects , Mitochondria/metabolism , Molecular Targeted Therapy/methods , Neoplasms, Experimental/drug therapy , Neoplasms, Experimental/immunology , Neoplasms, Experimental/pathology , Oxidation-Reduction , Oxidative Phosphorylation/drug effects , Programmed Cell Death 1 Receptor/immunology , T-Lymphocytes, Cytotoxic/drug effects , T-Lymphocytes, Cytotoxic/immunology , T-Lymphocytes, Cytotoxic/metabolism
12.
Sci Rep ; 7(1): 2335, 2017 05 24.
Article in English | MEDLINE | ID: mdl-28539670

ABSTRACT

High fat diet (HFD)-induced metabolic disorders may lead to emotional disorders. This study aimed to explore the effect of simvastatin (SMV) and bezafibrate (BZ) on improving HFD-induced emotional changes, and tried to identify their different mechanisms. The intraperitoneal glucose tolerance test (IPGTT) was used to evaluate glucose control ability; and behavior tests including open field tests (OFT), forced swimming tests (FST), tail suspension tests (TST) and sucrose preference (SPT), were then performed to evaluate emotional changes. Serum samples were collected for the LC-MS based metabolomics analysis to explore the emotional-related differential compounds; we then evaluated the effect of the drugs. The abnormal serum metabolic profiling and emotional changes caused by HFD in mice was alleviated by SMV treatment, whereas BZ only affected the emotional disorder. The improvement of cannabinoid analogues and then produced influences on the endocannabinoid system, which may be a potential mechanism SMV action. BZ promoted tryptophan-serotonin pathway and inhibited tryptophan-kynurenine pathway, which may be its mechanism of action. Here, we proposed a shed light on the biological mechanisms underlying the observed effects, and identified an important drug candidate for the treatment of emotional disorders induced by HFD.


Subject(s)
Bezafibrate/administration & dosage , Depression/drug therapy , Simvastatin/administration & dosage , Stress, Psychological/drug therapy , Animals , Behavior, Animal/drug effects , Depression/blood , Depression/pathology , Diet, High-Fat/adverse effects , Glucose Tolerance Test , Hindlimb Suspension , Hippocampus/drug effects , Hippocampus/metabolism , Male , Mice , Serotonin/metabolism , Signal Transduction/drug effects , Stress, Psychological/blood , Stress, Psychological/pathology , Swimming , Tryptophan/metabolism
13.
Virol J ; 14(1): 96, 2017 05 25.
Article in English | MEDLINE | ID: mdl-28545573

ABSTRACT

BACKGROUND: PPAR agonists are often used in HBV infected patients with metabolic disorders. However, as liver-enriched transcriptional factors, PPARs would activate HBV replication. Risks exsit in such patients. This study aimed to assess the influence of commonly used synthetic PPAR agonists on hepatitis B virus (HBV) transcription, replication and expression through HBV replicative mouse models, providing information for physicians to make necessary monitoring and therapeutic adjustment when HBV infected patients receive PPAR agonists treatment. METHODS: The HBV replicative mouse model was established by hydrodynamic injection of HBV replicative plasmid and the mice were divided into four groups and treated daily for 3 days with saline, PPAR pan-agonist (bezafibrate), PPARα agonist (fenofibrate) and PPARγ agonist (rosiglitazone) respectively. Their serum samples were collected for ECLIA analysis of HBsAg and HBeAg and real-time PCR analysis of Serum HBV DNA. The liver samples were collected for DNA (Southern) filter hybridization of HBV replication intermediates, real-time PCR analysis of HBV mRNA and immunohistochemistry (IHC) analysis of hepatic HBcAg. The alternation of viral transcription, replication and expression were compared in these groups. RESULT: Serum HBsAg, HBeAg and HBV DNA were significantly elevated after PPAR agonist treatment. So did the viral replication intermediates in mouse livers. HBV mRNA was also significantly increased by these PPAR agonists, implying that PPAR agonists activate HBV replication at transcription level. Moreover, hepatic HBcAg expression in mouse livers with PPAR agonist treatment was elevated as well. CONCLUSION: Our in vivo study proved that synthetic PPAR agonists bezafibrate, fenofibrate and rosiglitazone would increase HBV replication. It suggested that when HBV infected patients were treated with PPARs agonists because of metabolic diseases, HBV viral load should be monitored and regimens may need to be adjusted, an antiviral therapy may be added.


Subject(s)
Bezafibrate/administration & dosage , Enzyme Activators/administration & dosage , Fenofibrate/administration & dosage , Hepatitis B virus/physiology , Peroxisome Proliferator-Activated Receptors/agonists , Thiazolidinediones/administration & dosage , Virus Replication , Animals , DNA, Viral/blood , Enzyme-Linked Immunosorbent Assay , Hepatitis B Surface Antigens/blood , Hepatitis B e Antigens/blood , Male , Mice, Inbred BALB C , Models, Animal , Polymerase Chain Reaction , Rosiglitazone , Viral Load
14.
J Vet Intern Med ; 31(3): 717-722, 2017 May.
Article in English | MEDLINE | ID: mdl-28382723

ABSTRACT

BACKGROUND: Bezafibrate (BZF) is effective in the treatment of hypertriglyceridemia in human patients, but there are no data on its use in dogs. OBJECTIVE: To assess the safety of BZF in hyperlipidemic dogs and its efficacy in decreasing serum triglyceride (TG) and cholesterol (CHO) concentrations. ANIMALS: Forty-six dogs, 26 females and 20 males, mean (±SD) age of 9 (±3) years, with TG ≥150 mg/dL (33 dogs also were hypercholesterolemic [>300 mg/dL]). METHODS: Prospective, uncontrolled clinical trial. Dogs were treated with bezafibrate once daily, using 200 mg tablets at a dosage of 4-10 mg/kg (depending on body weight). Serum TG and CHO concentrations and alanine aminotransferase (ALT) and creatine kinase (CK) activity before and after 30 days of treatment were compared. RESULTS: Sixteen dogs (34.8%) had primary hyperlipidemia, and 30 dogs (65.2%) had secondary hyperlipidemia (including spontaneous hyperadrenocorticism [41.3%, n = 19/46], chronic treatment with glucocorticoids [10.8%, n = 5/46], and hypothyroidism [15.2%, n = 7/46]). After 30 days, serum TG concentration normalized (<150 mg/dL) in 42 dogs (91.3%) and CHO concentration normalized (<270 mg/dL) in 22 of 33 dogs (66.7%). There was no difference in baseline TG concentration between the primary and secondary hyperlipidemia subgroups, but the decrease in TG concentration after treatment was greater in the primary hyperlipidemia subgroup. No adverse effects were observed, but ALT activity decreased significantly after 30 days of treatment. CONCLUSIONS AND CLINICAL IMPORTANCE: Over 30 days, BZF was safe and effective in treatment of primary and secondary hyperlipidemia in dogs.


Subject(s)
Bezafibrate/therapeutic use , Dog Diseases/drug therapy , Hyperlipidemias/veterinary , Hypolipidemic Agents/therapeutic use , Administration, Oral , Animals , Bezafibrate/administration & dosage , Dog Diseases/blood , Dogs , Female , Hyperlipidemias/drug therapy , Hypolipidemic Agents/administration & dosage , Male , Prospective Studies , Treatment Outcome
15.
Arch Gerontol Geriatr ; 69: 31-37, 2017.
Article in English | MEDLINE | ID: mdl-27886564

ABSTRACT

AIMS: To explore the association of C-reactive protein (CRP) plasma levels with subsequent cognitive performance and decline among elderly individuals with pre-existing cardiovascular disease (CVD), and to assess the role of cerebrovascular indices in this relationship. METHODS: CRP levels were measured in a subgroup of individuals with chronic CVD, who previously participated in a secondary prevention trial. Cognitive performance was evaluated 14.7±1.9 and 19.9±1.0years after entry to the trial. A validated set of computerized cognitive tests was used (Neurotrax Computerized Cognitive Battery) to assess performance globally and in memory, executive function, visuospatial and attention domains. Linear regression and mixed models were used to assess the relationship of CRP plasma levels with cognitive scores and decline, respectively. In addition, we tested whether cerebrovascular reactivity, carotid intima media thickness and presence of carotid plaques modify these associations. RESULTS: Among 536 participants (mean age at the first cognitive evaluation 72.6±6.4years; 95% males), CRP at the top tertile vs. the rest was associated with subsequent poorer performance overall (ß=-2.2±1.0; p=0.031) and on tests of executive function and attention (ß=-2.3±1.1; p=0.043 and ß=-2.0±1.4; p=0.047, respectively). Moreover, CRP levels were positively related to a greater decline in executive functions (ß=-2.4±1.1; p=0.03). These associations were independent of potential confounders and were not modified by cerebrovascular indices. CONCLUSION: Our findings suggest that systemic chronic inflammation, potentially associated with underlying atherosclerosis, is related to cognitive impairment and decline two decades later, in elderly individuals with pre-existing CVD.


Subject(s)
Attention/physiology , C-Reactive Protein/metabolism , Cardiovascular Diseases/blood , Cognition/physiology , Cognitive Dysfunction/blood , Aged , Bezafibrate/administration & dosage , Biomarkers/blood , Cardiovascular Diseases/complications , Cardiovascular Diseases/prevention & control , Carotid Intima-Media Thickness , Cognitive Dysfunction/complications , Cognitive Dysfunction/diagnosis , Dose-Response Relationship, Drug , Female , Humans , Hypolipidemic Agents/administration & dosage , Inflammation/blood , Inflammation/complications , Israel/epidemiology , Male , Middle Aged , Prevalence
16.
Hum Mol Genet ; 25(11): 2269-2282, 2016 06 01.
Article in English | MEDLINE | ID: mdl-27008868

ABSTRACT

Huntington's disease (HD) is a devastating illness and at present there is no disease modifying therapy or cure for it; and management of the disease is limited to a few treatment options for amelioration of symptoms. Recently, we showed that the administration of bezafibrate, a pan-PPAR agonist, increases the expression of PGC-1α and mitochondrial biogenesis, and improves phenotype and survival in R6/2 transgenic mouse model of HD. Since the R6/2 mice represent a 'truncated' huntingtin (Htt) mouse model of HD, we tested the efficacy of bezafibrate in a 'full-length' Htt mouse model, the BACHD mice. Bezafibrate treatment restored the impaired PPARγ, PPARδ, PGC-1α signaling pathway, enhanced mitochondrial biogenesis and improved antioxidant defense in the striatum of BACHD mice. Untreated BACHD mice show robust and progressive motor deficits, as well as late-onset and selective neuropathology in the striatum, which was markedly ameliorated in the BACHD mice treated with bezafibrate. Our data demonstrate the efficacy of bezafibrate in ameliorating both neuropathological features and disease phenotype in BACHD mice, and taken together with our previous studies with the R6/2 mice, highlight the strong therapeutic potential of bezafibrate for treatment of HD.


Subject(s)
Huntingtin Protein/genetics , Huntington Disease/drug therapy , PPAR delta/biosynthesis , PPAR gamma/biosynthesis , Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha/biosynthesis , Animals , Bezafibrate/administration & dosage , Corpus Striatum/drug effects , Corpus Striatum/pathology , Disease Models, Animal , Humans , Huntington Disease/genetics , Huntington Disease/pathology , Mice , Mice, Transgenic , Mitochondria/drug effects , Mitochondria/genetics , Organelle Biogenesis , PPAR delta/genetics , PPAR gamma/genetics , Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha/antagonists & inhibitors , Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha/genetics , Signal Transduction/drug effects
17.
Nutrition ; 31(10): 1255-9, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26333891

ABSTRACT

OBJECTIVES: The aim of this study was to compare the ketogenic effect of the peroxisome proliferator-activated receptor-α stimulator, bezafibrate (BEZA), alone or in combination with medium-chain triacylglycerols (MCTs) in healthy adults. METHODS: Eighteen healthy adults completed the study: 10 were given a therapeutic dose of BEZA (400 mg/d) for 8 wk followed by a further 4 wk of BEZA (400 mg/d) plus MCT (60 g/d). Eight other participants were given MCT alone (60 g/d) for 4 wk. All participants underwent identical metabolic study days: (a) pretreatment (the control), and after (b) BEZA combined with MCT (BEZA+MCT) or (c) an equal dose of MCT only. On the metabolic study days, a standard breakfast and lunch were given and blood samples were taken hourly to measure plasma ketones, glucose, and fatty acids. RESULTS: The combination of BEZA+MCT increased ketones twofold during the metabolic study day. The addition of BEZA increased early ketogenic efficiency of MCT by 2.5-fold but did not result in higher peak or mean concentration of ketones during the metabolic study day. No other differences were seen in plasma metabolites or insulin during metabolic study days. On the final metabolic study day, MCT or BEZA+MCT had different effects on the plasma acetoacetate-to-ß-hydroxybutyrate ratio compared with control. CONCLUSIONS: BEZA mildly potentiated the ketogenic action of MCT but did not increase peak plasma ketone concentration or overall ketone production during the metabolic study day.


Subject(s)
Bezafibrate/administration & dosage , Hypolipidemic Agents/administration & dosage , Ketones/metabolism , Triglycerides/administration & dosage , 3-Hydroxybutyric Acid/blood , Acetoacetates/blood , Adult , Aged , Blood Glucose/analysis , Drug Therapy, Combination , Fatty Acids/blood , Female , Healthy Volunteers , Humans , Male , Middle Aged
18.
J Hepatobiliary Pancreat Sci ; 22(10): 766-70, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26173026

ABSTRACT

BACKGROUND: Primary sclerosing cholangitis (PSC) is a chronic cholestatic disease. Medical treatments must be devised to avoid or postpone liver transplantation in PSC patients. No clinical trial has prospectively explored the efficacy of bezafibrate in PSC patients. METHODS: We conducted a prospective study of 12-week bezafibrate treatment, with pre- and post-treatment observation periods, in PSC patients. Bezafibrate was prescribed at 200 mg b.i.d. The primary endpoint was defined as improvements in liver function test (LFT) data after bezafibrate treatment. Changes in LFT data during the study period were assessed every 6 weeks. RESULTS: Fifteen patients were enrolled as planned, and 11 completed the study protocol. Biliary enzyme levels improved in all patients after bezafibrate treatment for 12 weeks. Hepatic enzyme levels improved in only seven of the 11 patients, and the efficacy of bezafibrate in PSC patients was thus 64%. LFT data (alkaline phosphatase and alanine aminotransferase levels) were reduced after bezafibrate treatment (both P < 0.05 by Wilcoxon's signed-rank test), and both significantly increased after bezafibrate cessation (both P < 0.01). CONCLUSIONS: Bezafibrate effectively improved LFT data in 64% of PSC patients. This is the first prospective clinical trial to evaluate the effect of bezafibrate in PSC patients.


Subject(s)
Bezafibrate/administration & dosage , Cholangitis, Sclerosing/diagnosis , Cholangitis, Sclerosing/drug therapy , Administration, Oral , Adult , Aged , Cholangiopancreatography, Endoscopic Retrograde/methods , Chronic Disease , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Follow-Up Studies , Hospitals, University , Humans , Japan , Liver Function Tests , Magnetic Resonance Imaging/methods , Male , Middle Aged , Prospective Studies , Severity of Illness Index , Statistics, Nonparametric , Treatment Outcome
19.
Cancer Res ; 75(12): 2530-40, 2015 Jun 15.
Article in English | MEDLINE | ID: mdl-25943877

ABSTRACT

The redeployed drug combination of bezafibrate and medroxyprogesterone acetate (designated BaP) has potent in vivo anticancer activity in acute myelogenous leukemia (AML) and endemic Burkitt lymphoma (eBL) patients; however, its mechanism-of-action is unclear. Given that elevated fatty acid biosynthesis is a hallmark of many cancers and that these drugs can affect lipid metabolism, we hypothesized that BaP exerts anticancer effects by disrupting lipogenesis. We applied mass spectrometry-based lipidomics and gene and protein expression measurements of key lipogenic enzymes [acetyl CoA carboxylase 1 (ACC1), fatty acid synthase (FASN), and stearoyl CoA desaturase 1 (SCD1)] to AML and eBL cell lines treated with BaP. BaP treatment decreased fatty acid and phospholipid biosynthesis from (13)C D-glucose. The proportion of phospholipid species with saturated and monounsaturated acyl chains was also decreased after treatment, whereas those with polyunsaturated chains increased. BaP decreased SCD1 protein levels in each cell line (0.46- to 0.62-fold; P < 0.023) and decreased FASN protein levels across all cell lines (0.87-fold decrease; P = 1.7 × 10(-4)). Changes to ACC1 protein levels were mostly insignificant. Supplementation with the SCD1 enzymatic product, oleate, rescued AML and e-BL cells from BaP cell killing and decreased levels of BaP-induced reactive oxygen species, whereas supplementation with the SCD1 substrate (and FASN product), palmitate, did not rescue cells. In conclusion, these data suggest that the critical anticancer actions of BaP are decreases in SCD1 levels and monounsaturated fatty acid synthesis. To our knowledge, this is the first time that clinically available antileukemic and antilymphoma drugs targeting SCD1 have been reported.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/pharmacology , Fatty Acids, Monounsaturated/metabolism , Leukemia/drug therapy , Lymphoma/drug therapy , Stearoyl-CoA Desaturase/antagonists & inhibitors , Stearoyl-CoA Desaturase/metabolism , Bezafibrate/administration & dosage , Cell Line, Tumor , HL-60 Cells , Humans , K562 Cells , Leukemia/metabolism , Lipid Metabolism/drug effects , Lymphoma/metabolism , Medroxyprogesterone Acetate/administration & dosage , Prognosis
20.
Am J Gastroenterol ; 110(3): 423-31, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25732417

ABSTRACT

OBJECTIVES: The aim of this study was to assess the long-term prognosis, efficacy, and safety of combination therapy using ursodeoxycholic acid (UDCA) and bezafibrate (BF) for primary biliary cirrhosis (PBC) patients exhibiting dyslipidemia. METHODS: We performed a prospective, randomized, controlled, multicenter study to compare the long-term clinical results between combination therapy and UDCA monotherapy for patients refractory to UDCA monotherapy. Twenty-seven consecutive PBC patients were enrolled. RESULTS: The median treatment period in the UDCA and UDCA+BF groups was 107 and 110 months, respectively. The serum alkaline phosphatase (ALP) levels and the Mayo risk score in the combination therapy group (mean 290 IU/l and 0.91, respectively) were significantly lower than those in the UDCA monotherapy group (mean 461 IU/l and 1.42, respectively) at 8 years after the beginning of the study (P<0.05). The serum creatinine levels in the combination therapy group (mean 0.94 mg/dl) were significantly higher than those in the UDCA monotherapy group (mean 0.56 mg/dl) at 8 years after the beginning of the study (P<0.05). However, the survival rate was not significantly different between the groups. We observed dose reduction or discontinuation of the administration of BF, but not UDCA, due to renal dysfunction or muscle pain. CONCLUSIONS: Long-term combination therapy significantly improved the serum ALP levels and the Mayo risk score. However, the survival rate was not significantly different between the groups. In addition, long-term combination therapy significantly increased the serum creatinine levels. We should pay close attention to adverse events during this long-term combination therapy.


Subject(s)
Bezafibrate , Dyslipidemias/drug therapy , Liver Cirrhosis, Biliary/drug therapy , Myalgia , Renal Insufficiency , Ursodeoxycholic Acid , Alkaline Phosphatase/blood , Bezafibrate/administration & dosage , Bezafibrate/adverse effects , Cholagogues and Choleretics/administration & dosage , Cholagogues and Choleretics/adverse effects , Creatinine/blood , Dose-Response Relationship, Drug , Drug Monitoring/methods , Drug Therapy, Combination , Dyslipidemias/complications , Female , Humans , Hypolipidemic Agents/administration & dosage , Hypolipidemic Agents/adverse effects , Liver Cirrhosis, Biliary/complications , Male , Middle Aged , Myalgia/blood , Myalgia/chemically induced , Prognosis , Renal Insufficiency/blood , Renal Insufficiency/chemically induced , Survival Rate , Time , Treatment Outcome , Ursodeoxycholic Acid/administration & dosage , Ursodeoxycholic Acid/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...